Table 1.
Baseline characteristics and observed survival outcomes of cancer cohorts, by cancer site and age group, diagnosis in Sweden during 1981-1990 with follow-up until 2020.
| Observed Outcomes | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer Cohort | 10 y | Lifetime or 40 y | Censoring Proportion at Time Points (%) | ||||||||
| Type | Age Group (y) | Median Age (y) | n | RMST (y) | Survival (%) | LE (y) | Survival (%) | 2 y | 3 y | 5 y | 10 y |
| Colon | 18–59 | 53 | 3,627 | 5.59 | 44.20 | 14.38 | 9.19 | 64.52 | 57.29 | 50.23 | 44.36 |
| 60–69 | 65 | 6,230 | 5.19 | 36.51 | 9.16 | 0.00 | 62.02 | 55.51 | 46.61 | 36.57 | |
| 70–99 | 77 | 14,826 | 4.05 | 18.65 | 5.04 | 0.00 | 55.22 | 46.47 | 35.38 | 18.70 | |
| Breast | 18–59 | 49 | 15,991 | 8.10 | 67.44 | 21.63 | 19.36 | 91.75 | 86.88 | 78.88 | 67.53 |
| 60–69 | 65 | 10,996 | 7.82 | 60.44 | 14.52 | 0.00 | 90.31 | 85.46 | 76.78 | 60.49 | |
| 70–99 | 77 | 16,782 | 5.75 | 28.78 | 7.39 | 0.00 | 78.32 | 69.16 | 54.30 | 28.73 | |
| Melanoma | 18–59 | 45 | 5,662 | 8.70 | 78.79 | 27.26 | 37.95 | 93.64 | 90.43 | 85.39 | 78.89 |
| 60–69 | 65 | 2,638 | 7.63 | 60.51 | 14.67 | 0.00 | 87.45 | 81.73 | 74.03 | 60.58 | |
| 70–99 | 76 | 3,194 | 5.53 | 28.66 | 7.29 | 0.00 | 74.20 | 64.84 | 50.94 | 28.71 | |
| Prostate | 18–59 | 57 | 1,808 | 6.35 | 38.65 | 10.59 | 1.62 | 82.58 | 73.34 | 58.74 | 38.83 |
| 60–69 | 66 | 10,423 | 6.10 | 33.74 | 8.49 | 0.00 | 80.74 | 71.41 | 57.37 | 33.84 | |
| 70–99 | 77 | 29,749 | 4.47 | 13.90 | 5.02 | 0.00 | 68.69 | 56.86 | 38.94 | 13.94 | |
| CML | 18–59 | 44 | 359 | 4.71 | 20.42 | 8.16 | 6.73 | 69.36 | 57.66 | 39.83 | 20.61 |
| 60–69 | 66 | 218 | 3.21 | 4.64 | 3.50 | 0.00 | 56.88 | 43.58 | 22.48 | 5.05 | |
| 70–99 | 77 | 372 | 1.88 | 1.08 | 1.90 | 0.00 | 33.06 | 22.04 | 10.48 | 1.08 | |
CML, chronic myeloid leukemia; LE, life expectancy; RMST, restricted mean survival time; y, year(s). If survival proportion was not yet zero by 40 y, the 40-y RMST was reported instead of LE.